Description
Tirzepatide is a synthetic dual-agonist peptide engineered to bind two key incretin receptors simultaneously — the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual mechanism makes it one of the most extensively studied compounds in modern metabolic research. In controlled laboratory settings, Tirzepatide is examined for its combined activity across GLP-1 and GIP signaling pathways, including its influence on insulin secretion, glucose regulation, and energy-metabolism markers. Its unique twin-receptor profile positions it as a key reference compound in metabolic, endocrinology, and incretin-signaling research.
Important Note
Tirzepatide is not approved for human consumption, medical use, or diagnostic purposes. It is supplied strictly for laboratory research only. Handling should be performed by qualified professionals in an appropriate controlled research setting.
Dosage Reference Chart (Research Use Only)
| Form | Suggested Research Concentration | Example Preparation | Notes |
|---|---|---|---|
| Lyophilized Powder | 10mg per vial | Reconstitute with sterile or bacteriostatic water | Store dry at −20°C until use |
| Reconstituted Solution | 2–5 mg/mL | Dissolve to target concentration for experiments | Stable at 2–8°C for 2–3 weeks; do not freeze once reconstituted |
| Experimental Dosing | Variable by study | Adjust according to study design | Preclinical / literature-based models only |
Features & Properties
Synthetic dual-agonist peptide targeting both GLP-1 and GIP receptors
Studied for combined activity across two incretin signaling pathways
Examined for its influence on insulin secretion and glucose regulation
A leading reference compound in metabolic and incretin research
Twin-receptor profile distinguishes it from single-agonist peptides
Supplied as lyophilized powder for maximum stability during storage and transport
Manufactured under research-grade quality standards with HPLC-verified purity ≥99%
Storage & Stability
Lyophilized: stable for up to 24 months at −20°C
Reconstituted solution: stable for 2–3 weeks at 2–8°C
Avoid repeated freeze–thaw cycles
Protect from light and moisture at all times
Usage Restrictions
For laboratory research use only
Not approved for human consumption, medical use, or diagnostic purposes
Handling should be performed by qualified professionals in controlled research settings
Store securely and keep out of reach of children
Do not handle during pregnancy or breastfeeding
Frequently Asked Questions
Q1. What does each vial contain? Each vial contains 10mg of Tirzepatide, supplied as a sterile lyophilized powder.
Q2. What is the appearance of the product? A fine white to off-white lyophilized powder at the base of the vial.
Q3. How should it be stored? Before reconstitution: store at −20°C, stable up to 24 months. After reconstitution: store refrigerated at 2–8°C, stable 2–3 weeks.
Q4. How is it reconstituted? It is soluble in sterile or bacteriostatic water. Use aseptic technique during reconstitution to maintain integrity.
Q5. Is it sterile? Yes, it is manufactured and sealed under sterile laboratory conditions. Proper sterile handling is still required during reconstitution and use.
Q6. Is this product for human use? No. This compound is intended for research use only. It is not approved for medical or veterinary use.
Q7. What purity standard is used? Every batch is HPLC-verified to ≥99% purity and third-party tested.
Q8. What is the vial packaging? A clear borosilicate glass vial sealed with a butyl rubber stopper and aluminum crimp closure.
Q9. How stable is the product during shipping? The lyophilized form is stable under standard shipping conditions. Transfer to long-term storage (−20°C) immediately upon arrival.
Q10. Who can handle this product? Only qualified laboratory researchers with appropriate training in peptide handling and proper protective equipment.
Reviews
There are no reviews yet.